Taking alendronate for at least 8 years could potentially reduce one’s risk for type 2 diabetes (T2D) by more than one-half when compared with never taking the agent, according to findings presented at the annual meeting of the European Association for the Study of Diabetes. The study team identified more than 163,000 people diagnosed with T2D in Denmark between 2008 and 2018, and compared them with more than 490,000 people without diabetes. Those who took alendronate for 8 years or more had a 53% lower risk for developing diabetes, compared with those who never took the agent, the researchers found. They also discovered that the longer someone took alendronate, the lower their odds of developing diabetes.